1. Home
  2. CDNA vs GERN Comparison

CDNA vs GERN Comparison

Compare CDNA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$19.44

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.80

Market Cap

900.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDNA
GERN
Founded
1998
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
900.1M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
CDNA
GERN
Price
$19.44
$1.80
Analyst Decision
Buy
Buy
Analyst Count
7
7
Target Price
$26.67
$3.00
AVG Volume (30 Days)
656.6K
13.9M
Earning Date
02-24-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.22
N/A
Revenue
$357,998,000.00
$183,403,000.00
Revenue This Year
$14.49
$146.80
Revenue Next Year
$11.32
$30.21
P/E Ratio
$16.16
N/A
Revenue Growth
14.46
522.13
52 Week Low
$10.96
$1.04
52 Week High
$25.55
$2.84

Technical Indicators

Market Signals
Indicator
CDNA
GERN
Relative Strength Index (RSI) 48.29 76.49
Support Level $18.81 $1.55
Resistance Level $21.00 $1.69
Average True Range (ATR) 1.11 0.11
MACD -0.13 0.03
Stochastic Oscillator 40.03 92.24

Price Performance

Historical Comparison
CDNA
GERN

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: